Advance Preclinical Research Using Particle Beamlines
The First Image-Guided Platform for Preclinical Particle Therapy Research
SARRP Beamline offers the first image-guided platform designed for preclinical particle therapy research. The open cabinet design was developed to be installed on rails to align with a modified proton experimental beamline from a clinical system. The system has been developed to enable in vivo investigations of radiobiological effects of proton beams, comparative studies between proton and X-ray beams, and investigations into novel proton treatment methods. The SARRP Beamline X-ray imaging and delivery components can be customized to meet the needs of your research program.
SARRP Beamline Builds on SARRP
SARRP Beamline takes the SARRP platform one step further because it enables researchers to perform experiments using their clinical set-up, directly on their preclinical model. Using SARRP Beamline, investigators can align the proton beam to the SARRP isocenter within 0.24mm. The system can also be configured on rails for easy adaptability to the beamline. Leading cancer researchers at both the University of Washington and the University of Pennsylvania are already using SARRP Beamline to support advanced radiation research using their clinical proton therapy equipment.
REQUEST MORE INFORMATION
Learn more about SARRP Beamline and how Xstrahl can help you meet your particle therapy research goals.
WATCH OUR SARRP SERIES
Introducing SARRP Beamline by Xstrahl
SARRP Beamline offers the first image-guided platform designed for beamline irradiation. Built on the robust and established SARRP platform, SARRP Beamline provides CT guidance and robotic alignment for small animal experiments.
SARRP Beamline offers the first image-guided research platform designed for beamline irradiation.
Find out more about why Xstrahl will work tirelessly for you
Request More Information
Interested in Learning More?
Find out how you can implement cost-effective radiation treatment in your practice quickly and easily.